https://doi.org/10.4081/reumatismo.2006.59

Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab

Vol. 58 No. 1 (2006)
Abstract Views: 888
PDF: 873
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Giuseppe D'Alessandro
office@pagepress.org
Maria Rosaria Bianco
Spiridon Politis
Celestino Ferrandina
Giuseppe Rossi
Emanuele Altomare
Anti TNF-a drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-a molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab. (2006). Reumatismo, 58(1), 59-61. https://doi.org/10.4081/reumatismo.2006.59

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.